Clinical trials: Sjogren Syndrome
Sjögren´s Syndrome
Low Dose Cyclosporin A in Primary Sjögren Syndrome
Sandimmun optoral (Cyclosporin A) is used for the musculoskeletal manifestations of Primary Sjögren Syndrome
- Trial name
- CYPRESS (NCT01693393)
- Testing
- Cyclosporine A
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Charite University, Berlin, Germany
Primary Sjögren Syndrome, Lymphoma, Non-Hodgkin
Biomarkers in Primary Sjögren's Syndrome
The clinical spectrum of primary Sjogren Syndrome (pSS)ranges from sicca syndrome to systemic involvement (extraglandular manifestations), including a large number of manifestations that may be the form of presentation or appear…
- Trial name
- pSS (NCT03765593)
- Testing
- Biopsy Salivary Gland
- Volunteers
- 100 people
- Sponsor
- National Council of Scientific and Technical Research, Argentina
Primary Sjögren Syndrome, Sarcopenia
Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome
The aim of this study is to evaluate the frequency of probable sarcopenia and sarcopenia in patients with primary Sjögren syndrome and to investigate the effects of sarcopenia on functional status, muscle strength, and quality of…
- Trial name
- NCT07804719
- Testing
- dexa, hand grip strength, myostatin, follistatin
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Primary Sjogren´s Syndrome, Myositis
Exercise in Sjogren, Myositis and Takayasu's Arteritis
Exercise may improve physical capacity and health parameters in Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis. Therefore, this study aims to investigate the role of an exercise training program in patients with…
- Trial name
- NCT01501019
- Testing
- Exercise training
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Systemic Lupus Erthematosus, Systemic Vasculitis
Rare AutoImmune SElf-management Programme Development
The rare autoimmune rheumatic diseases (RAIRDs) are life-long multi-system diseases that are life or organ threatening. RAIRDs can impair quality of life similar to chronic diseases such as heart failure.
- Conditions
- Systemic Lupus Erthematosus, Systemic Vasculitis, Inflammatory Myositis, Systemic Sclerosis (SSc)
- Trial name
- RAISE (NCT06642870)
- Testing
- Non-interventional study
- Where
- United Kingdom
- Volunteers
- 360 people
- Sponsor
- University of the West of England
Dry Eye, Sjogren Syndrome
Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome
Evaluation of the effect of topical application of Tacrolimus 0.03% (FK506) eye drops versus Cyclosporine 0.05% eye drops in treatment of dry eye in Secondary Sjogren Syndrome.
- Trial name
- NCT03865888
- Testing
- Cyclosporins, Tacrolimus
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Pavly Moawd
Sjogren's Syndrome
Comprehensive Evaluation of Clinical and Biopsychosocial Characteristics in Primary Sjögren's Disease
Following the guidance of individuals with primary Sjögren's Syndrome who receive diagnosis, routine medical care, and treatment management, the evaluations will be performed once by the researchers and will take approximately…
- Trial name
- NCT06410742
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Primary Sjögren Syndrome
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren's syndrome.
- Trial name
- NCT07375524
- Testing
- ESG206
- Where
- 21 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage.
- Conditions
- Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06828042
- Testing
- anti-CD19 CAR T cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Congenital Heart Block, Neonatal Lupus
Preventive IVIG Therapy for Congenital Heart Block
Neonatal lupus (NL) is the name given to a group of conditions that can affect the babies of mothers who have certain autoantibodies against components of the body's cells that are called SSA/Ro and SSB/La.
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block
- Trial name
- PITCH (NCT00460928)
- Testing
- intravenous immune globulin (IVIG)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Sjogren Syndrome
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
- Trial name
- NEPTUNUS-2 (NCT05349214)
- Testing
- VAY736
- Where
- 146 sites in United States, Argentina and 24 more
- Volunteers
- 506 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Inflammatory Myopathy
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
- Trial name
- NCT06794008
- Testing
- BCMA-CD19 CAR-T therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Sjogren Syndrome, Dry Eye Syndrome
Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops
Aqueous deficiency dry eye is mainly caused by Sjogren syndrome (SS), an autoimmune, chronic, inflammatory and systemic disease which affects most commonly the lacrimal and salivary glands.The ocular treatment is focused in…
- Trial name
- NCT01850979
- Testing
- Tacrolimus, Olive Oil
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Sao Paulo General Hospital
Xerostomia, Sjogren Syndrome
Green Tea Lozenges for the Management of Dry Mouth
The goal of this proposal is to investigate the effectiveness of a Medical College of Georgia patent pending formulation of natural plant extracts on patients with xerostomia.
- Conditions
- Xerostomia, Sjogren Syndrome, Dry Mouth
- Trial name
- NCT01647737
- Testing
- MighTeaFlow, Xylitol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Augusta University
Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.
- Conditions
- Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
- Trial name
- NCT07184450
- Testing
- BCMA/CD70-targetd CAR-T
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Primary Sjogren, Secondary Sjogren
A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment
The purpose of this study is to assess and compare the safetyness and efficacy of pilocarpine drops versus artificial saliva as symptomatic treatment for dry mouth and dry eyes caused by SS in a multicenter, doubleblind…
- Conditions
- Primary Sjogren, Secondary Sjogren, Xerostomia
- Trial name
- NCT00438048
- Testing
- pilocarpine, Artificial Saliva
- Where
- Chile
- Volunteers
- 76 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06978647
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Polymyalgia Rheumatica, Sjogren's Syndrome
Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome
To determine the phenotype of patients having PMR symptoms and primary Sjogren syndrome (pSS), we used a French national call to identify patients combining both diseases and collected retrospective clinical and biological data.
- Trial name
- PASS (NCT05312944)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Brest
Sjogren Syndrome
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
- Trial name
- NEPTUNUS-1 (NCT05350072)
- Testing
- VAY736
- Where
- 77 sites in United States, Austria and 16 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye, Sjogren Syndrome
Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye
Dry eye is a chronic condition that decreases function and affect visual function with severe discapacity until now treatments are based in artificial eye drops.
- Trial name
- NCT02257957
- Testing
- PRP injection, Standard care Hyaluronic acid eye drops
- Volunteers
- 30 people
- Sponsor
- Universidad Nacional de Colombia